- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Patent holdings for IPC class C07D 403/04
Total number of patents in this class: 7391
10-year publication summary
|
564
|
548
|
538
|
578
|
591
|
542
|
497
|
556
|
406
|
246
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Patent GmbH | 5818 |
150 |
| Bristol-myers Squibb Company | 4884 |
122 |
| Novartis AG | 10829 |
112 |
| Boehringer Ingelheim International GmbH | 4644 |
90 |
| Janssen Pharmaceutica N.V. | 3384 |
87 |
| AstraZeneca AB | 2900 |
78 |
| Bayer AG | 3336 |
77 |
| F. Hoffmann-La Roche AG | 7920 |
76 |
| Syngenta Crop Protection AG | 6067 |
73 |
| Takeda Pharmaceutical Company Limited | 2696 |
68 |
| Merck Sharp & Dohme LLC | 3742 |
68 |
| LG Chem, Ltd. | 17639 |
67 |
| Dana-Farber Cancer Institute, Inc. | 2568 |
63 |
| Hoffmann-La Roche Inc. | 3428 |
60 |
| Rohm and Haas Electronic Materials Korea Ltd. | 330 |
59 |
| Genentech, Inc. | 3983 |
56 |
| Vertex Pharmaceuticals Incorporated | 1595 |
53 |
| Araxes Pharma LLC | 92 |
50 |
| Abbvie Inc. | 1800 |
46 |
| Syngenta Participations AG | 1900 |
45 |
| Other owners | 5891 |